Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal assumptions,...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Physiological Pharmacokinetic Models: Assumption with Protein Binding01:13

Physiological Pharmacokinetic Models: Assumption with Protein Binding

Physiological models with protein binding in pharmacokinetics offer a sophisticated approach to understanding drug disposition. These models consider drug-protein interactions, enabling them to effectively predict drug concentrations in different organs and tissues. This precision aids in accurate drug dosing, providing a significant advantage over conventional models. A key process within these models is equilibration, which ensures that drug concentrations achieve a steady state within the...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "Assessment of the applicability of the threshold of toxicological concern for per- and polyfluoroalkyl substances" [Regul. Toxicol. Pharmacol. 133 (2022) 105190].

Regulatory toxicology and pharmacology : RTP·2026
Same author

Nitroparaffin transcriptional profiles and toxicokinetics support chemical-specific carcinogenicity assessment.

Regulatory toxicology and pharmacology : RTP·2026
Same author

Physiologically based pharmacokinetic modeling of oseltamivir in pregnant rhesus macaques to inform clinical dosing across trimesters.

Regulatory toxicology and pharmacology : RTP·2025
Same author

Lung cancer mortality among aircraft manufacturing workers with long-term, low-level, hexavalent chromium exposure.

Journal of occupational and environmental hygiene·2025
Same author

The Feasibility and Acceptability of a Clinical Pharmacist-delivered Intervention to Reduce Bothersome Health Symptoms from Polypharmacy and Alcohol Use and Communicate Risk among People with HIV: Pilot Study Protocol.

AIDS and behavior·2024
Same author

Pharmacokinetic analysis of nicotine and its metabolites (cotinine and trans-3'-hydroxycotinine) in male Sprague-Dawley rats following nose-only inhalation, oral gavage, and intravenous infusion of nicotine.

Toxicological sciences : an official journal of the Society of Toxicology·2024

Related Experiment Video

Updated: Jun 28, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

12.6K

In vitro and computational approaches to predict developmental toxicity: Integrating PBPK models with cell-based

Marjory Moreau1, Todor Antonijevic1, John Carter Hall1

  • 1ScitoVation, LLC, Research Triangle Park, NC 27713, USA.

Toxicology and Applied Pharmacology
|June 6, 2025
PubMed
Summary

This study integrates new in vitro methods with pharmacokinetic modeling to predict chemical developmental toxicity. These approaches offer a quantitative, animal-free alternative for human health risk assessment.

Keywords:
Developmental toxicityNew approach methodologyPBPK modelinghuman induced pluripotent stem cellsin vitro to in vivo extrapolation

More Related Videos

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

6.7K
Cytotoxicity Assays with Zebrafish Cell Lines
08:22

Cytotoxicity Assays with Zebrafish Cell Lines

Published on: January 6, 2023

6.3K

Related Experiment Videos

Last Updated: Jun 28, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

12.6K
Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure
08:25

Advanced 3D Liver Models for In vitro Genotoxicity Testing Following Long-Term Nanomaterial Exposure

Published on: June 5, 2020

6.7K
Cytotoxicity Assays with Zebrafish Cell Lines
08:22

Cytotoxicity Assays with Zebrafish Cell Lines

Published on: January 6, 2023

6.3K

Area of Science:

  • Toxicology and Chemical Safety Assessment
  • Reproductive and Developmental Toxicology
  • New Approach Methodologies (NAMs)

Background:

  • The field of chemical safety assessment is moving away from animal testing towards New Approach Methodologies (NAMs).
  • Existing in vitro methods for teratogenic potential lack quantitative frameworks for human health risk assessment.
  • Connecting in vitro results to human exposure levels remains a challenge for public health risk evaluation.

Purpose of the Study:

  • To quantitatively predict developmental toxicity thresholds using prenatal developmental toxicity assays.
  • To assess the predictive capacity of in vitro assays for nine reproductive toxicants and one non-teratogen.
  • To establish quantitative frameworks linking in vitro data to human equivalent doses (HEDs).

Main Methods:

  • Utilized a three-tiered physiologically based pharmacokinetic (PBPK) model.
  • Translated in vitro concentrations from ReproTracker, Stemina DevTOX quickPredict™, and developmental neurotoxicity (DNT) battery assays into HEDs.
  • Compared in vitro-derived HEDs with rodent study-based HEDs (LOAELs) and human exposure data.

Main Results:

  • Demonstrated that integrating PBPK modeling with specific in vitro assays (Reprotracker, Stemina DevTOX quickPredict™, DNT) can quantitatively predict developmental toxicity.
  • The developed framework successfully translated in vitro findings to human equivalent doses for risk assessment.
  • The study provides a viable alternative to animal testing for developmental toxicity evaluation.

Conclusions:

  • The integration of PBPK modeling with in vitro assays advances animal-free developmental toxicity assessment.
  • This approach enhances the human relevance of chemical safety evaluations.
  • Further research into developmental toxicity mechanisms and computational translation methods is needed for robust human risk evaluation.